Straumann Holding Ag · SIX:STMN

Straumann — Q1 2014 Earnings Presentation

14 slides from Straumann's earnings presentation, May 12, 2014

  1. Slide 1: Turning a new page

    12.05.2014 Turning a new page Disclaimer This presentation contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of t

  2. Slide 2: Regional and business review

    12.05.2014 Regional and business review Steady outperformance except for time of restructuring 10% Q1: Revenue of 8% CHF 180m (+6% in l.c.) 6% 4% 2% 2014 guidance 0% -2% -4% -6% -8% Rightsizing and re- -10% organisation measures -12% Market for tooth replacement & restoration (leading implant compan

  3. Slide 3: Good growth in Q1 across all regions; Europe contributes >40% to growth

    12.05.2014 Good growth in Q1 across all regions; Europe contributes >40% to growth In CHF million 2.9% in CHF 6.0% in l.c. 2.2 2.2 1.7 ‐5.2 4.1 179.8 174.8 Change in l.c. 169.6 (3.1%) 4.1% 5.2% 8.3% 28.6% Revenues Q1 FX Effect Revenues Q1 Europe North America APAC ROW Revenues Q1 2013 2013 @ FX 2014

  4. Slide 4: A new attractive pricing concept

    12.05.2014 A new attractive pricing concept ‘More value, same price’ campaign 2013 2014  Roxolid® established as standard material Ceramic  Upgrade to Roxolid® SLA ® and SLActive® Roxolid implants with LOXIM™ transfer piece at SLActive same price as titanium equivalents with old transfer piece Ti

  5. Slide 5: Good strategic progress

    12.05.2014 Good strategic progress Pressure to adapt to new market realities General practitioner (GP) segment gaining importance with different needs than the specialists segments Female dentists becoming more and more important Value players gaining share on behalf of premium players Young dentist

  6. Slide 6: Investment in MegaGen to drive expansion in value implant segment in Asia

    12.05.2014 More US generalists assume an active role 11 Quelle: iData Research, US data, 2012 Investment in MegaGen to drive expansion in value implant segment in Asia  Founded in 2002, MegaGen is one of Korea’s fastest- growing dental implant companies  Straumann purchases 3%-interest-bearing con

  7. Slide 7: Combining strengths with botiss to provide complete regenerative solutions worldwide

    12.05.2014 Combining strengths with botiss to provide complete regenerative solutions worldwide  Exclusive rights for Straumann to distribute botiss products in most Western/Central European countries and the Americas  Botiss to distribute Emdogain® in Germany, parts of Eastern Europe and Middle E

  8. Slide 8: Separate-brand strategy to address premium and value segments

    12.05.2014 Separate-brand strategy to address premium and value segments Germany Spain Brazil Germany Distribution 30% 49% 51% & call option 2014 2013 2012 2013 Canada Germany Taiwan Korea 44% CADCAM Convertible bond Convertible bond 2011 2014 2014 2014 Common platform for technology & production Pr

  9. Slide 9: The "Swiss made" has affected our financials...

    12.05.2014 The “Swiss made” has affected our financials... Costs 1.8 1.6 1.4 1.2 1 0.8 Sales 0.6 2008 2009 2010 2011 2012 2013 USDCHF EURCHF JPYCHF 17 ...but we made a first step towards our goal of restoring historic l.c. margins Underlying EBIT margin 27.4% 25% 20.7% 20% @ 2013 FX rates 15-20% 18.

  10. Slide 10: 2014 outlook helped by an exciting roll-out program

    12.05.2014 2014 outlook helped by an exciting roll-out program Value-adding solutions to meet clinician and patient needs abutments Ceramic New SR implant High Ceramic implants Smaller, less Fixed Level of sophistication invasive implants immediate edentulous solutions Implants for Straumann Roxolid

  11. Slide 11: Outlook for 2014 unchanged

    12.05.2014 Outlook for 2014 unchanged Barring unforeseen circumstances  We expect the global implant market to develop positively in 2014 and our revenue to grow in the low- single-digit range (l.c.).  After a promising Q1, we expect a softer Q2 given the later Easter break this year.  We will co

  12. Slide 12: First step towards goal of restoring historic margin levels

    12.05.2014 First step towards goal of restoring historic margin levels Underlying EBIT margin 27.4% 25% >20% 20.7% 20% @ 2013 FX rates 15-20% 18.2% 15% 14.5% 10-15% 10-15% 10-15% 10% 2008 2012 2013 2014/15 Straumann Dental benchmark1 23 1 Peers comprise Nobel Biocare, Dentsply, Patterson, Henry Sche

  13. Slide 13: Calendar of upcoming events

    12.05.2014 Calendar of upcoming events 2014 11-12 June Vontobel Swiss Conference Interlaken/CH 13 June Deutsche Bank Swiss & German Conference Berlin 26 August Half-year 2014 results conference Basel HQ 23 October Third quarter sales Audio webcast 2015 24 February Full-year 2014 results conference B

  14. Slide 14: Organization adapted to match market development

    12.05.2014 Organization adapted to match market development Global workforce (year-end)  Headcount reduced by 300 to pre- 2 517 2 452 economic crisis level 2 361  Overall restructuring/downsizing costs in 2 201 2 170 2 217 2013 amount to a net CHF 8m1  80% of leavers had found new jobs by year-en

Straumann — Q1 2014 Earnings Presentation on 6ix